logo

For the Inventor, By the Inventor

Mulheim a.d. Ruhr, Germany

Christa Hegele-Hartung

This inventor holds 18 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Schering Aktiengesellschaft, Bayer Schering Pharma Ag, Novo Nordisk A/s. Active years: 1996-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christa Hegele-Hartung. Retrieved from https://idiyas.com/inventor/christa-hegele-hartung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18

% Patents Active = 50.0

Average Co-Inventor Count = 5.4

ph-index = 6

Forward Citations = 208(Granted Patents)


Location History:

  • Berlin, DE (1996 - 2004)
  • Mulheim a.d. Ruhr, DE (2004)
  • Mülheim/Ruhr, DE (2005)
  • Muelheim a. d. Ruhr, DE (2002 - 2006)
  • Muelheim/Ruhr, DE (2005 - 2008)
  • Muelheim a. d Ruhr, DE (2008)

Company Filing History:

goldMedal17 out of 1,409 
 
Schering Aktiengesellschaft
 patents
silverMedal1 out of 192 
 
Bayer Schering Pharma Ag
 patents
bronzeMedal1 out of 1,806 
 
Novo Nordisk A/s
 patents
where one patent can have more than one assignee

Years Active: 1996-2008

Loading Chart...
Areas of Expertise:
Non-Steroidal Progestins
Selective Estrogens
Benzocycloheptenes
Estratrienes
Meiosis-Regulating Medicaments
Anti-Estrogen Activity
Pharmaceutical Preparations
Fertility Regulation
Estradiol Derivatives
Compounds Production
11β-Substituted Estratrienes
18 patents (USPTO):Explore Patents
1. 7388006 - Non-steroidal progesting (2008-06-17),
2. 7378404 - 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens (2008-05-27),
3. 7145015 - Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents (2006-12-05),
4. 7109360 - 16-hydroxyestratrienes as selectively active estrogens (2006-09-19),
5. 6958327 - 18 Norsteroids as selectively active estrogens (2005-10-25),
6. 6916921 - Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds (2005-07-12),
7. 6878750 - Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents (2005-04-12),
8. 6844336 - 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity (2005-01-18),
9. 6794409 - Use of ER&bgr;-selective ligands for regulating fertility and compounds useful therefor (2004-09-21),
10. 6790842 - 11&bgr; LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11&bgr; LONG-CHAIN SUBSTITUTED ESTATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS (2004-09-14),
11. 6677324 - Combination preparation of estrogen and anti-estrogen (2004-01-13),
12. 6495607 - Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents (2002-12-17),
13. 6271403 - 7&agr;-(xi-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7&agr;-(xi-aminoalkyl-estratrienes as well as their use for the production of pharmaceutical agents (2001-08-07),
14. 6229029 - 11&bgr;-aryl substituted 14,17-ethanoestratriens, method for the production of these compounds and their use in the production of medicaments (2001-05-08),
15. 5986115 - 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, (1999-11-16),

Title: Christa Hegele-Hartung: Pioneering Innovator in Pharmaceutical Solutions

Introduction:

Christa Hegele-Hartung, a visionary inventor based in Muelheim a.d. Ruhr, Germany, is a trailblazer in the world of pharmaceutical solutions with a keen focus on innovation and sustainability. With 18 patents to his name, Christa's contributions have significantly impacted the fields of contraception, hormone replacement therapy, and gynecological disorders.

Latest Patents:

1. Non-steroidal progesting: Christa's invention of non-steroidal progestins aims at selectively modulating progesterone receptor-mediated effects in various target tissues, particularly in uterine tissue versus breast tissue. These progestins, when combined with estrogens, have diverse applications in contraception, hormone replacement therapy, and the treatment of gynecological disorders.

2. 8β-hydrocarbyl-substituted estratrienes: Another notable invention by Christa involves the development of 8β-substituted estratrienes as selective estrogens. These compounds exhibit higher affinity to estrogen receptor preparations of rat prostates than to those of rat uteri. They are primarily designed for preferential action on bone health and stimulation of specific receptors and transporters.

Career Highlights:

Throughout his career, Christa Hegele-Hartung has made significant contributions while working at renowned companies such as Schering Aktiengesellschaft and Bayer Schering Pharma Ag. His expertise and dedication to innovation have led to groundbreaking advancements in the pharmaceutical industry.

Collaborations:

Christa has collaborated with esteemed colleagues like Rolf Bohlmann and Karl-Heinrich Fritzemeier, fostering a culture of innovation and excellence in their research and development endeavors. Together, they have pushed boundaries and created impactful solutions in pharmaceutical sciences.

Conclusion:

In conclusion, Christa Hegele-Hartung emerges as a pioneer in pharmaceutical innovation, with a remarkable track record of patents aimed at improving healthcare outcomes and quality of life. His passion for driving positive change through research and invention sets him apart as a visionary inventor shaping the future of healthcare technologies and solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…